From the Department of Orthopedic Surgery, NYU Langone Orthopedic Hospital, New York, NY (Konda, Parola, Perskin, Fisher, Ganta, and Egol) and Department of Orthopedic Surgery, Jamaica Hospital Medical Center, New York, NY (Konda, Ganta, and Egol).
J Am Acad Orthop Surg. 2023 Apr 1;31(7):349-356. doi: 10.5435/JAAOS-D-22-00582. Epub 2023 Jan 18.
The purpose of this study is to identify optimal threshold hemoglobin (Hgb) and hematocrit (Hct) laboratory values to transfuse hip fracture patients.
A consecutive series of hip fracture patients were reviewed for demographic, clinical, and cost data. Patients receiving an allogeneic transfusion of packed red blood cells (pRBCs) were grouped based on last Hct or Hgb (H&H) value before first transfusion. Multivariate logistic regressions of H&H quantile were performed to predict "good outcomes," a composite binary variable defined as admissions satisfying (1) no major complications, (2) length of stay below top tertile, (3) cost below median, (4) no mortality within 30 days, and (5) no readmission within 30 days. Odds ratios (OR) for "good outcomes" were calculated for each H&H quantile.
One thousand four hundred ninety-six hip fracture patients were identified, of which 598 (40.0%) were transfused with pRBCs. Patients first transfused at Hgb values from 7.55 to 7.85 g/dL ( P = 0.043, OR = 2.70) or Hct values from 22.7 to 23.8% ( P = 0.048, OR = 2.63) were most likely to achieve "good outcomes."
The decision to transfuse patients should be motivated by Hgb and Hct laboratory test results, given that transfusion timing relative to surgery has been shown to not affect outcomes among patients matched by trauma risk score. Surgeons should aim to transfuse hip fracture patients at Hgb levels between 7.55 g/dL and 7.85 g/dL or Hct levels between 22.7% and 23.8%. These transfusion thresholds have the potential to lower healthcare costs without compromising quality, ultimately resulting in less costly, efficacious care for the patient.
Level III.
本研究旨在确定为髋部骨折患者输血的最佳血红蛋白(Hgb)和血细胞比容(Hct)实验室值。
回顾性分析了一系列连续的髋部骨折患者的人口统计学、临床和成本数据。根据首次输血前的最后一次 Hct 或 Hgb(H&H)值,将接受异体输血的患者分为红细胞悬液(pRBC)组。使用 H&H 分位数的多变量逻辑回归来预测“良好结果”,这是一个由五个二进制变量组成的复合变量,定义为(1)无主要并发症;(2)住院时间低于上三分位数;(3)费用低于中位数;(4)30 天内无死亡;(5)30 天内无再入院。计算每个 H&H 分位数的“良好结果”的比值比(OR)。
共纳入 1496 例髋部骨折患者,其中 598 例(40.0%)接受了 pRBC 输血。首次输血时 Hgb 值为 7.55-7.85 g/dL(P=0.043,OR=2.70)或 Hct 值为 22.7%-23.8%(P=0.048,OR=2.63)的患者最有可能获得“良好结果”。
鉴于手术时机与输血时机对风险评分匹配的患者的结局无影响,应根据 Hgb 和 Hct 实验室检测结果来决定是否为患者输血。外科医生应将髋部骨折患者的 Hgb 水平目标设定在 7.55 g/dL 至 7.85 g/dL 之间,或 Hct 水平目标设定在 22.7%至 23.8%之间。这些输血阈值有可能在不影响质量的情况下降低医疗保健成本,最终为患者提供更经济有效的治疗。
III 级。